Engineering PD-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging.

ABSTRACT:

Background

Programmed cell death 1 (PD-1) belongs to immune checkpoint proteins ensuring negative regulation of the immune response. In non-small cell lung cancer (NSCLC), the sensitivity to treatment with anti-PD-1 therapeutics, and its efficacy, mostly correlated with the increase of tumor infiltrating PD-1⁺ lymphocytes. Due to solid tumor heterogeneity of PD-1⁺ populations, novel low molecular weight anti-PD-1 high-affinity diagnostic probes can increase the reliability of expression profiling of PD-1⁺ tumor infiltrating lymphocytes (TILs) in tumor tissue biopsies and in vivo mapping efficiency using immune-PET imaging.

Methods

We designed a 13 kDa β-sheet Myomedin scaffold combinatorial library by randomization of 12 mutable residues, and

SUBMITTER: Mierzwicka JM 

PROVIDER: S-EPMC11071268 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature